Navigation Links
New Treatments Emerging from Immune and Inflammatory Disease R&D Pipelines

New York, NY (PRWEB) June 19, 2012

A new syndicated TrendsmemeTM Report: Immune and Inflammatory Diseases has been released by Medmeme, LLC., a global leader in comprehensive, integrated medical and science information database platforms. The report details the trends and potential for drug developers in immune/inflammatory diseases particularly focusing on three key disease indications: RA (rheumatoid arthritis), IBD (inflammatory bowel disease), and SLE (systemic lupus erythematosus). According to the Centers for Disease Control and Prevention (CDC) and the Arthritis Foundation (AF), between 1.3 million and 1.5 million people in the United States have RA. The CDC also reports than mortality rates among RA patients are nearly 2.5 times higher than those in the general population, owing primarily to excess risk of cardiovascular disease, infections, and some cancers. The Medmeme report illustrates that treatment of these three indications commands much of the R&D effort and market in this therapeutic category and represents recent, notable scientific progress. R&D for the three indications also offers a window into issues that are relevant broadly across the category.

Medmeme CEO Mahesh Naithani describes the marketplace: ”The value of the immune/inflammatory disease pharmaceutical markets has been driven by very intense research to characterize pathological factors, which was then translated into development of highly targeted biological therapies. Commercial success has come to the companies and brands that have contributed to this clinical revolution. Just three drugs in this therapeutic area— Amgen/Pfizer’s Enbrel, Johnson & Johnson’s Remicade, and Abbott’s Humira— respectively were the seventh, eighth, and ninth highest selling pharmaceutical brands worldwide in 2010, with combined sales exceeding $18 billion. Need for new treatments and market potential have encouraged many companies to be active such as Roche, Merck, Biogen Idec, AstraZeneca, Eli Lilly, Novartis, Regeneron, GlaxoSmithKline, Astellas, and Sanofi, others too. Another major driver of success in immune/inflammatory disease markets has been company strategies of label expansion into multiple disease areas, particularly for biologics like the TNF-a inhibitors.”

Scientific data from the Medmeme database shows that discussion centering on late-stage RA emerging therapies in medical conference presentations and journal publications increased in 2011. This increase is primarily attributable to novel non-TNF-alpha target drugs such as: AstraZeneca’s fostamatinib, an oral Syk kinase inhibitor, Novartis’s secukinumab, a monoclonal antibody against IL-17A, and Pfizer’s tofacitinib, an oral JAK inhibitor. Of these three frontrunner emerging therapies, Pfizer’s tofacitinib may reach market this year. The drug was submitted for U.S. approval to treat RA at the end of 2011.

The syndicated TrendsmemeTM Report: Immune and Inflammatory Diseases can be purchased separately, or, along with other MedMeme reports in the new series, at discounted pricing. To learn more, contact us, or see our website,

Medmeme, LLC                                     
Yan Barshay, Executive Vice President                 
+1 212-725-5992                                             
Ray Wright, Vice President, Sales
+ 1 508-278-4595

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
2. Research May Point to New Obesity Treatments
3. Researchers make promising discovery in pursuit of effective lymphoma treatments
4. Study examines treatments for relieving breathing difficulties among patients with lung effusions
5. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
6. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
7. 1960s-era anti-cancer drug points to treatments for Lou Gehrigs disease
8. Rejuv Medical In Sartell, MN Now Offering Stem Cell Treatments
9. MDS researchers join forces to advance patient treatments and outcomes
10. How does the immune system fight off threats to the brain? New research yields fresh insight
11. Regulatory immune cell diversity tempers autoimmunity in rheumatoid arthritis
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
(Date:11/27/2015)... ... , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his search ... one of Joplin's most famous and beautiful concert posters. The concert was held on ... Arbor. The According to Hawley, "It is hard to believe that Joplin's stardom was ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction ... , “We wake up every day excited to rebuild lives and it’s an honor ...
(Date:11/26/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the world-class Asterisk based ... efficiency and reliability. , The new Q-Suite 6 platform is based on the latest ... itself into a specific piece of software for many key components of the suite. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
(Date:11/25/2015)... , Nov. 25, 2015  The American ... and Gynecologists (ACOG), and the March of Dimes ... Protecting Our Infants Act of 2015 ... number of newborns born exposed to drugs, such ... the bill,s introduction, all three organizations have worked ...
(Date:11/25/2015)... MELVILLE, N.Y. , Nov. 25, 2015  Henry ... products and services to office-based dental, medical and animal ... Dental (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion ... industry,s broadest array of open solutions designed to help ... Click here for a schedule of ...
Breaking Medicine Technology: